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PEET CE estimates for new MS drugs differ greatly depending
upon whether Swedish or Nova Scotia natural history data are
used. As all other factors are held constant, these large CE dif-
ferences are due entirely to differences in rates of disability 
progression.
PNL23
PROBABILISTIC SENSITIVITY ANALYSIS OF A COST-
EFFECTIVENESS MODEL FOR TRIPTANS (5-HT AGONISTS)
Livengood KB,Ambegaonkar AJ
Pﬁzer Inc, New York, NY, USA
OBJECTIVE: The primary objective of the analysis was to simul-
taneously account for and characterize the uncertainty in a cost-
effectiveness model of current triptan (5-HT agonist) therapy for
migraine headache. METHODS: Common components of cost
and effect were identiﬁed as migraine incidence, overall market
share for each triptan, migraine response rate at two hours per
triptan [milligram] strength, migraine recurrence rate per triptan
strength, and the percentage of patients on each triptan strength.
Components speciﬁc to cost alone were the number of migraine
attacks/patient/month and wholesale acquisition cost (WAC) per
triptan strength. Effect was deﬁned as a successfully treated
migraine attack. Costs were determined for every triptan and not
per triptan strength. Uncertainty in the cost-effectiveness ratio
was modeled using Monte Carlo simulation techniques, speciﬁ-
cally utilizing inverse transformation of the component cumula-
tive distribution functions. One thousand random draws were
taken from each of the assumed component distributions, and
cost and effect were computed for each draw. Cost, effect, and
their random components were log-10 transformed, and ordi-
nary least squares regression was performed using cost/effect as
the dependent variable and the components of cost and effect 
as independent variables. Distributional assumptions were logi-
stic-normal for proportional components, Poisson for the
attacks/patient/month component, and uniform for the WAC
component. RESULTS: There was a 10% change in the cost-
effectiveness ratio with a 10% change in attacks/patient/month
and WAC, while the change in the ratio was less than 8% with
a 10% change in the response and recurrence rates. All other
components were insigniﬁcant in their effect. CONCLUSIONS:
The cost-effectiveness model appears to be stable under the
assumptions of its construction, since cost/effect did not change
at a rate greater than the rate of change for any of the signiﬁ-
cant components of cost and effect.
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DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY
EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND
ESTIMATE PREVALENCE, INCIDENCE,AND MORTALITY
Nelson LS1, Gunter MJ1, Robinson S1, Holden EW2
1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2ORC Macro,
Atlanta, GA
OBJECTIVES: The purpose of this study was to develop and
apply computer algorithms to an administrative dataset to iden-
tify the prevalence and incidence of epilepsy, and epilepsy-related
mortality within a managed care organization. METHODS: The
study consisted of three phases: exploratory, conﬁrmatory, and
application of the algorithm to estimate prevalence, incidence,
and mortality. Exploratory: Potential epilepsy patients were iden-
tiﬁed based on epilepsy-related codes in administrative data; a
random sample of charts were reviewed to conﬁrm epilepsy
cases. An algorithm was developed utilizing combinations of
epilepsy-related diagnoses, procedures, and medications based
on chart review results. Conﬁrmatory: The algorithm derived in
the exploratory phase was then applied to a new dataset from
the same MCO; a second conﬁrmatory chart review was con-
ducted. Further algorithm reﬁnement was accomplished by
applying logistic regression models to the combined chart review
data from both phases. Application: The ﬁnal models were
applied to 1-, 3-, and 5-year datasets to identify prevalent and
incident cases, which were then linked to a statewide death reg-
istry to derive mortality estimates. RESULTS: The best model
used diagnoses and anti-epileptic drugs as predictors, had a pos-
itive predictive value of 84% (sensitivity, 82%;, speciﬁcity 94%),
and correctly classiﬁed 90% of the cases. Prevalence rates of
7–10/1000 across the 1-, 3-, and 5-year datasets, depending on
age, gender, and ethnicity, were obtained. Annualized incidence
for members continuously enrolled for 3 years was 47/100,000
and 71/100,000 for members continuously enrolled for 5 years.
Crude mortality rates were 2–2.5 times higher for epilepsy
patients identiﬁed with the best model compared to controls.
CONCLUSIONS: The algorithm developed in this project can
be used to monitor trends in incidence, prevalence, and mortal-
ity to inform decisions critical to improving the health care and
overall quality of life for epilepsy patients.
OSTEOPOROSIS
OSTEOPOROSIS—Clinical Outcomes Studies
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THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON
THE INITIATION OF AN OSTEOPOROSIS-RELATED
PHARMACOTHERAPY: A POPULATION-BASED ANALYSIS
Caetano PA, Metge CJ, Leslie WD
University of Manitoba, Winnipeg, MB, Canada
OBJECTIVE: The inﬂuence of bone mineral density (BMD)
assessment on a woman’s decision to initiate an osteoporosis-
related pharamcotherapy has not been analyzed at the popula-
tion-level through the use of administrative databases. Through
linkage of a BMD database (containing the results of nearly all
BMD measurements performed in the province of Manitoba
since 1990), we measured the inﬂuence of such testing on the
likelihood of initiating an osteoporosis-related pharmacotherapy
(OSRx) in post-menopausal women. METHODS: Hospital,
physician, pharmaceutical, clinical (bone mineral density results)
and demographic data for women continuously residing in 
Manitoba from 1997 through 2002 were obtained from provin-
cial administrative databases. Outcome variable: Initiation of an
OSRx (including hormone replacement therapy [HRT], bispho-
sphonates, selective estrogen receptor modulators[SERM], and
calcitonin). Women with a prescription claim for an OSRx
between 1997–1998 were excluded to restrict the analysis to
incident users. Explanatory variables: BMD test (yes/no), prior
osteoporotic fracture (hip, spine, rib, or vertebral) after age 50,
age, income quintile, and urban vs. rural residence. Likelihood
of initiating an OSRx was analyzed using the Cox proportional
hazards regression. RESULTS: A total of 112,464 women satis-
ﬁed the inclusion criteria, of which, 7.5% received at least one
BMD test and 12.5% (14,031 women) initiated at least one
OSRx within the study period (39.8% HRT; 51.9% bisphos-
phonates; 5.8% SERM; and 2.5% calcitonin). Predictors of
OSRx initiation included (but are not limited to): BMD test in
the previous 6 months (RR 4.05 (95% CL, 3.88–4.22)); and an
osteoporosis-related fracture after age 50 (RR 1.35 (95% CL,
1.29–1.42)). Women with BMD results indicating osteoporosis
at the spine or hip were more likely to initiate an OSRx [RR =
7.72 (95% CL 6.77–8.79) and RR = 6.14 (95% CL 5.44–6.92)
spine & hip, respectively]. CONCLUSIONS: Receipt of a BMD
assessment increases the likelihood a woman will initiate an
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OSRx, particularly in those women diagnosed with osteopenia
and/or osteoporosis according to their test results.
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DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF
EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN
FIVE COUNTRIES
Piercy J1,Tompkins R2, Kay S2, Karavali M2
1Adelphi Group, Macclesﬁeld, Cheshire, United Kingdom; 2Adelphi
Group Products, Macclesﬁeld, Cheshire, United Kingdom
OBJECTIVES: Patients and physicians are sometimes asked to
ﬁll in questionnaires concerning clinical events and resource util-
isation such as tests and investigations. This study analyses dif-
ferences in reporting of diagnostic tests and clinical events by a
matched sample of doctors and patients in the management of
osteoporosis in ﬁve countries. METHODS: The data are drawn
from the Disease Speciﬁc Programme in Osteoporosis, which col-
lected information about osteoporosis management from both
doctors and patients. The study included 7349 patients (aged
50–80 with osteoporosis or suspected osteoporosis), treated by
709 doctors in France, UK, Germany, Italy, USA. For each doctor
record, patients were asked to ﬁll out a self-completion ques-
tionnaire. 2646 matched patient self-completion records were
obtained. Key data items collected from both doctors and
patients were X-rays, bone mineral density (BMD) scanning, and
fractures. Differences between matched physician and patient
responses were tested using the Fisher Exact test. RESULTS:
Patients were signiﬁcantly more likely to recall X-rays than
doctors (41.2% vs. 33.8%, p < 0.01). This difference was sig-
niﬁcant in each country except Italy and Germany, although
patients still reported higher levels of testing. No signiﬁcant dif-
ferences were found for BMD scanning other than the UK, where
patients reported a higher level of testing (65.0% vs. 44.0%, 
p < 0.01). Patients were less likely to report fractures (30.0% vs.
36.4%, p < 0.01). Statistically signiﬁcant differences were
observed in all countries except the USA. CONCLUSIONS: This
study demonstrates differences between physicians and patients
in terms of both resource use and events. Patients reported more
tests but less fractures than doctors. These ﬁndings have impli-
cations for economic evaluations. Evidence from patients must
be treated with caution, due to potential problems of recall bias
and/or misunderstanding of tests and events. The importance 
of using hard evidence for retrospective analysis cannot be 
overstated.
OSTEOPOROSIS
OSTEOPOROSIS—Cost Studies
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HEALTH CARE UTILIZATION AND EXPENDITURES: A STUDY
OF SEVERE OSTEOPOROSIS
Orsini LS1, Long S2, Pantos B3,Wang S1, Rousculp M3
1The Medstat Group, Inc, Cambridge, MA, USA; 2Medstat,
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OBJECTIVE: More than 1.5 million fractures occur due to
osteoporosis each year. This study examines the characteristics
of osteoporosis patients who incur an osteoporosis-related frac-
ture compared to osteoporosis patients who do not incur frac-
ture and estimates the economic burden associated with the
illness. METHODS: The study sample consisted of patients with
an osteoporosis diagnosis (733.0x) between January 1, 1998 and
December 31, 2000. Osteoporosis patients with both an osteo-
porosis diagnosis and a related fracture were classiﬁed as having
severe osteoporosis, all other osteoporosis patients were classi-
ﬁed as Non-Severe. Annual utilization and expenditures for the
Severe cohort were compared to the Non-severe cohort, as well
as to a group of patients without osteoporosis (Controls)
matched 3 :1 to the Severe osteoporosis cohort based on age,
gender, region, health plan type, and length of enrollment.
Patients with malignant neoplasm, carcinoma, or Paget’s disease
of bone were excluded from all groups. Exponential conditional
mean models were used to compute regression-adjusted total
expenditures across the groups and the differences in adjusted
expenditures were used to generate the economic burden of
illness estimates. RESULTS: Patients with Severe osteoporosis
incurred twice the amount of overall health care expenditures in
the study period compared to Non-Severe osteoporosis patients
and nearly three times that of the control group. Approximately
25% of the overall health care expenditures for the severe group
were osteoporosis-related expenditures, leading to the conclu-
sion that comorbid conditions in patients with severe osteo-
porosis contribute signiﬁcantly to overall health care costs. Some
of these comorbidity-related costs are likely due to pain-related
disorders, which occurred signiﬁcantly more frequently than in
the Non-Severe and Control cohorts. CONCLUSIONS: Osteo-
porosis-related expenditures, particularly those related to frac-
ture, were substantial. However, non-osteoporosis-related
expenditures to treat comorbid conditions constituted 75% of
the overall health care costs incurred in the year after an osteo-
porosis-related fracture and warrant further investigation.
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COST-EFFECTIVENESS OF LONG-TERM HORMONE
REPLACEMENT THERAPY (ESTROGEN PLUS PROGESTIN) IN
HEALTHY POSTMENOPAUSAL WOMEN FOR OSTEOPOROSIS
PREVENTION
Yu YF, Hay JW,Yu AP
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To examine the cost and effectiveness of long-
term hormone replacement therapy (HRT) in healthy post-
menopausal women for preventing osteoporosis. Although HRT
has been widely used for osteoporosis prevention, previous
studies on its cost-effectiveness showed controversial results.
Recently, the Women’s Health Initiative (WHI) study found sig-
niﬁcant clinical risks with HRT. METHODS: From a societal
perspective, resource consumption, incidence rates and relative
risks were collected for the following diseases in HRT-treated
and HRT-naïve women: breast cancer, colorectal cancer, CHD,
stroke, pulmonary embolism, dementia, and bone fractures.
Besides the WHI results, cost, utility and other clinical data were
from published literature, CDC vital statistics databases, and
SEER cancer statistics. Using a 3% annual discount rate, pro-
jected lifetime costs and quality-adjusted life years (QALYs) were
estimated by DEALE and backward induction methods and com-
pared in women with HRT vs. without HRT for each age group
at 5-year intervals. RESULTS: Under the base case assumptions,
HRT increased average lifetime treatment costs ($20,753 for
non-HRT group vs. $31,941 for HRT group), and yet reduced
average discounted quality adjusted life expectancy (10.18 years
for non-HRT group vs. 5.87 years for HRT group), indicating
that HRT use is an inferior strategy. These negative results were
largely attributed to the net increased risks in breast cancer and
CHD due to HRT. As age increased from 50 to 90, the incre-
mental costs increased from $2221 to $18,988, and loss in
QALYs decreased from 10.8 to 0.44 years. The model results
were relatively insensitive to reasonable parameter changes.
CONCLUSIONS: For healthy postmenopausal women, long-
term HRT to prevent osteoporosis raises overall treatment costs
